Maria Trojanowska, PhD
Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology (Arthritis)

PhD, Polish Academy of Sciences
MSc, University of Warsaw



Dr. Trojanowska’s research is aimed at understanding the molecular and cellular mechanisms that regulate ECM synthesis in healthy tissues and in pathological conditions such as fibrosis and tumorigenesis. The majority of her studies focus on the pathogenesis of scleroderma, an autoimmune disease characterized by vascular abnormalities and a prominent fibrosis of the skin. Her laboratory uses molecular and cellular approaches and various experimental models to elucidate the mechanisms responsible for uncontrolled ECM deposition and vessel degeneration in scleroderma. The second area of investigation is related to activation of tumor stroma. These studies examine the molecular mechanisms that mediate controlled regulation of ECM turnover in healthy connective tissue and are responsible for dysregulation of this process during tumorigenesis. Recent studies together with Dr. Lafyatis are examining the role of ER stress in systemic sclerosis.

Director
Boston University School of Medicine
Arthritis Center




Molecular mechanism of vasculopathy and fibrosis in scleroderma
05/06/2014 - 04/30/2019 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5R01AR042334-24

Preclinical assesment of dimethylfumarate (Tecfidera) as a novel therapeutic for SSC-PAH
04/01/2017 - 03/31/2019 (PI)
Scleroderma Foundation


TGF -beta receptor/Endoglin signaling and the origin of scleroderma fibroblasts
09/01/2015 - 08/31/2017 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
2R56AR044883-16

The Functional Biology of Oncostatin M (OSM) and Interleukin (IL)-6/ Soluble IL-6 Receptor in Endothelial Cells
08/24/2015 - 08/23/2016 (PI)
GlaxoSmithKline Research & Development Limited


TGF-Beta Receptor Signaling Scleroderma
10/01/2009 - 05/31/2014 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5R01AR044883-15

The Molecular Mechanisms of Fibrosis
08/10/1994 - 03/31/2013 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases
5R01AR042334-19




Yr Title Project-Sub Proj Pubs
2018 The molecular mechanism of vasculopathy and fibrosis in scleroderma 5R01AR042334-24 45
2017 The molecular mechanism of vasculopathy and fibrosis in scleroderma 5R01AR042334-23 45
2017 Project 2: Scleroderma-Associated Pulmonary Arterial Hypertension: The Role of the Oxidant State 2P50AR060780-06A1-6919 25
2016 The molecular mechanism of vasculopathy and fibrosis in scleroderma 5R01AR042334-22 45
2015 TGF-beta receptor/Endoglin signaling and the origin of scleroderma fibroblast 2R56AR044883-16
2015 The Role of ER Stress in Systemic Scleroderma 5P50AR060780-05-7134 25
2014 The molecular mechanism of vasculopathy and fibrosis in scleroderma 2R01AR042334-20A1 45
2014 The Role of ER Stress in Systemic Scleroderma 5P50AR060780-04-7134 25
2013 The Role of ER Stress in Systemic Scleroderma 5P50AR060780-03-7134 25
2012 TGF-beta receptor signaling in scleroderma 5R01AR044883-15 33
Showing 10 of 52 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Stawski L, Trojanowska M. Oncostatin M and its role in fibrosis. Connect Tissue Res. 2018 Jul 30; 1-10.View Related Profiles. PMID: 30056769.
     
  2. Saigusa R, Asano Y, Taniguchi T, Hirabayashi M, Nakamura K, Miura S, Yamashita T, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Trojanowska M, Sato S. Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells. Arthritis Res Ther. 2018 Feb 07; 20(1):23. PMID: 29415756.
     
  3. Stawski L, Marden G, Trojanowska M. The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway. J Immunol. 2018 Jan 01; 200(1):248-259.View Related Profiles. PMID: 29141862.
     
  4. Toyama T, Looney AP, Baker BM, Stawski L, Haines P, Simms R, Szymaniak AD, Varelas X, Trojanowska M. Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis. J Invest Dermatol. 2018 Jan; 138(1):78-88.View Related Profiles. PMID: 28870693.
     
  5. Looney AP, Han R, Stawski L, Marden G, Iwamoto M, Trojanowska M. Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis. Am J Respir Cell Mol Biol. 2017 Jul; 57(1):121-131.View Related Profiles. PMID: 28248553; DOI: 10.1165/rcmb.2016-0200OC;.
     
  6. Makino K, Makino T, Stawski L, Lipson KE, Leask A, Trojanowska M. Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Res Ther. 2017 Jun 13; 19(1):134.View Related Profiles. PMID: 28610597.
     
  7. Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis. J Invest Dermatol. 2017 Aug; 137(8):1671-1681.View Related Profiles. PMID: 28433542.
     
  8. Farina A, Peruzzi G, Lacconi V, Lenna S, Quarta S, Rosato E, Vestri AR, York M, Dreyfus DH, Faggioni A, Morrone S, Trojanowska M, Farina GA. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes. Arthritis Res Ther. 2017 Feb 28; 19(1):39.View Related Profiles. PMID: 28245863; DOI: 10.1186/s13075-017-1237-9;.
     
  9. Takahashi T, Asano Y, Sugawara K, Yamashita T, Nakamura K, Saigusa R, Ichimura Y, Toyama T, Taniguchi T, Akamata K, Noda S, Yoshizaki A, Tsuruta D, Trojanowska M, Sato S. Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. J Exp Med. 2017 Apr 03; 214(4):1129-1151. PMID: 28232470; DOI: 10.1084/jem.20160247;.
     
  10. Grzegorzewska AP, Seta F, Han R, Czajka CA, Makino K, Stawski L, Isenberg JS, Browning JL, Trojanowska M. Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci Rep. 2017 02 02; 7:41605.View Related Profiles. PMID: 28150703; DOI: 10.1038/srep41605;.
     
Showing 10 of 162 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 160 publications over 33 distinct years, with a maximum of 17 publications in 2017

YearPublications
19841
19872
19881
19891
19903
19911
19925
19931
19941
19953
19962
19973
19982
19992
20004
20014
20027
20035
200410
20056
20066
20076
200811
20093
201012
20116
20129
20139
20144
20156
20166
201717
20181
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Trojanowska's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department